logo
Ontario expands pension plan to self-employed doctors previously excluded

Ontario expands pension plan to self-employed doctors previously excluded

It's a shot in the arm for doctors at a time when Ontario is scrambling to ease a shortage that has left 2.5 million people without a family physician.
Since January, doctors with their own practices have been able to join the same pension plan enjoyed by colleagues who work in hospitals — and bring their receptionists, nurses and any other staff along for the ride to retirement.
Hundreds of self-employed physicians have expressed interest and more than 75 have taken steps to become part of the $123 billion Healthcare of Ontario Pension Plan, also known by its acronym pronounced 'hoop.'
While the opening wasn't created with the troublesome doctor shortage in mind, it can't hurt, says a senior executive.
'If the ability to access the defined-benefit pension like HOOPP is the reason for a physician to set up shop in or stay in Ontario, that's fantastic,' says Rachel Arbour, a lawyer and head of plan benefits, design and policy.
'But we're here to provide really good pensions and retirement for health-care workers, and this is one of the reasons why we looked at growing our plan to physicians,' she adds. 'We believe we play an important role in recruitment and retention. Health-care employers in our province can say to their staff 'we can offer you a great pension.''
The plan boasted a solid
9.7 per cent gain
on global investments last year on behalf of 475,000 members and retirees in health care across the province.
Opening the pension plan to self-employed physicians who have established their own medicine professional corporations and agree to pay a membership fee to the Ontario Hospital Association is the result of years of work and urging from within the health-care sector, including the Ontario Medical Association. The change to include self-employed doctors involved getting approval from Ontario's pension regulator and the Canada Revenue Agency.
The OMA offers a group retirement savings plan to its members — who include 31,500 practicing physicians — but recognizes that many would also like to have a traditional pension plan with defined benefits.
'It has a good track record,' says Kimberly Moran, a chartered accountant and the OMA's chief executive officer, of the HOOPP pension.
While the shortage of an estimated 3,500 family doctors has many root causes,
such as heavy workloads, long days and administrative paperwork
, Moran notes the new pension offering provides 'a little bit of help.'
Recognizing it was politically vulnerable because of the
doctor shortage
, Premier Doug Ford's Progressive Conservatives pledged $1.4 billion in new spending on the eve of Ontario's Feb. 27 election campaign for expanded primary health-care teams, with Health Minister Sylvia Jones acknowledging 'there's no doubt people have been waiting a long time, too long, frankly, to get connected to a family-care practitioner in their community.' Ford has also added more spaces in medical schools and a new medical school is opening at Toronto Metropolitan University in Brampton next fall, but will take years to produce fully trained doctors.
The OMA said 8,600 physicians have retired or left their practices since 2018, meaning two doctors are lost for every three new ones added to the health-care system.
As many jurisdictions around the world compete with each other for med school graduates, more than 750 doctors have reached out to a HOOPP hotline about the pension plan after reading full details posted on the organization's website.
They are encouraged to discuss the prospect of joining with their own financial advisors.
'Every doctor is going to have a slightly different set of circumstances they're going to have to work through and make sure that it makes sense for them,' says Moran.
Aside from paying a membership fee to the Ontario Hospital Association, which would not reveal the dollar value but said the cost is 'modest' for doctors, physicians joining the plan make contributions both as the employer and the employee, based on income. Those contributions are tax-deductible.
'It's about half-and-half in terms of doctors who are sole practitioners and those who have staff with them,' Arbour says. 'We would love the family physicians, their nurses, the receptionist, the whole bucket of people supporting that practice to come into our plan. The longer you're in our plan, the bigger your pension income will be upon retirement.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Are weight loss drugs safe? Learn some of the side effects
Are weight loss drugs safe? Learn some of the side effects

The Hill

time16-05-2025

  • The Hill

Are weight loss drugs safe? Learn some of the side effects

Weight loss drugs have become an increasingly popular, but controversial, way of quickly shedding extra pounds over the past few years. Part of that controversy deals with the side effects caused by some of the more well-known medications like Ozempic and Mounjaro. According to the Obesity Medicine Association (OMA), researchers are continually analyzing the pros and cons of these drugs. Here are some side effects of the eight FDA-approved weight loss drugs: Ozempic and Wegovy are the brand names of a drug known as semaglutide, a medication that, according to Harvard Health, has been prescribed for about two decades to treat Type 2 diabetes. Ozempic has become controversial over the past few years as overweight and obese patients have sought it out for weight loss, creating a shortage of the drug for those using it to control their diabetes. Wegovy is the brand name for a form of semaglutide that has since been approved for weight loss. Semaglutide, which mimics a natural hormone called GLP-1, helps regulate blood sugar while slowing down the emptying of the stomach and signaling satiety or fullness to the brain. The OMA reports that the most common complaint among patients using semaglutide is gastrointestinal issues like nausea. Other side effects include fatigue, dizziness, headache, bloating, belching and heartburn. An American Medical Association study has also found that GLP-1 agonists are associated with an increased risk of pancreatitis, bowel obstruction, and gastroparesis. While headlines have warned about an increase in suicidal ideation with semaglutide, a January 2024 study in Nature Medicine suggested 'a 49% to 73% lower risk of first-time or recurring suicidal ideations' compared with other obesity medications. Mounjaro and Zepbound are drugs known as tirzepatide. Mounjaro was approved in 2017 to treat Type 2 diabetes, while Zepbound was approved in more recent years to treat obesity. Like semaglutide, tirzepatide is a GLP-1 agonist that increases a person's feeling of fullness and helps them maintain a weight loss diet. It causes common mild symptoms like nausea, constipation, diarrhea and bloating, but the OMA reports more serious side effects like kidney problems up to and including kidney failure, gallbladder symptoms, pancreatitis and hypoglycemia. Manufacturer Eli Lilly warns, however, that Tirzepatide may cause thyroid tumors or thyroid cancer. Patients should monitor themselves for symptoms like neck swelling, hoarseness, problems swallowing and shortness of breath. Contrave is the brand name for a medication that combines two drugs, bupropion and naltrexone. Bupropion, which is marketed under the brand name Wellbutrin, is an antidepressant that is also known to reduce a person's appetite. Naltrexone, commonly sold under the brand names Revia and Vivitrol, is a medication used to treat drug and alcohol addiction. According to naltrexone works by blocking the euphoric, intoxicated feeling of alcohol and opioids. It also helps reduce the cravings for the substances. The OMA reports that patients should not be prescribed Contrave if they suffer from a seizure disorder or if they take opioids for chronic pain. The most common side effects of the drug are nausea, vomiting, constipation, diarrhea, headache, dizziness, dry mouth and insomnia. Saxenda is a medication containing liraglutide, a drug that mimics a person's natural hormones affecting hunger, digestion and feelings of fullness. It was approved by the FDA in 2017 to treat obesity in people 12 and older. The most common side effects of liraglutide are nausea, vomiting, constipation, diarrhea, headache, fatigue, dyspepsia, dizziness and abdominal pain. It can also cause increased heart rate, increased lipase, which is a pancreatic enzyme, and decreased kidney function. Qsymia is a medication that combines the drugs phentermine and topiramate. According to the OMA, phentermine has been around since 1959, making it the oldest and most widely used weight loss medication. The drug, which works in the brain as an appetite suppressant, is a stimulant similar to amphetamines and can be abused. It should not be used by patients who have suffered a stroke or who have heart disease, glaucoma or hyperthyroidism. The side effects of phentermine can be serious, including fast or irregular heart rate, headache, overstimulation, high blood pressure and tremors. It can also interact with several other drugs, including MAO inhibitors, alcohol, adrenergic neuron blockers and some anesthetic agents. When phentermine is combined with topiramate, an anticonvulsant, its effect on hunger is magnified. The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and dry mouth. Topiramate also carries a risk of birth defects, so it should not be taken during pregnancy. Qsymia was approved in 2021 for chronic weight management in adults. It was approved the following year for pediatric patients ages 12 and older who have a body mass index in the 95th percentile or greater. Imcivree, which is the brand name for setmelanotide, is approved by the FDA to treat patients suffering from severe obesity caused by rare genetic disorders. According to the National Institute of Health, setmelanotide is used to treat POMC, PCSK1 and LEPR deficiencies, which all lead to early-onset obesity. According to manufacturer Rhythm Pharmaceuticals, it is also used to treat Bardet-Biedl syndrome in patients aged 2 and older. Setmelanotide works by targeting the impaired MC4R pathway in the brain, which allows it to deliver messages to the brain that the body is satisfied and doesn't need more food. The National Institutes of Health (NIH) reports that it helps restore appetite control, reduces the patient's food intake and helps to control weight gain. It does not treat the underlying genetic defects that lead to obesity. The most common side effects of Imcivree are reactions at the injection site, hyperpigmentation, nausea, vomiting, headache, diarrhea, stomach pain and depression. More serious side effects include sexual dysfunction, depression, suicidal thoughts or actions and toxicity caused by benzyl alcohol, which is a preservative in Imcivree. Like most medications, it can also cause serious allergic reactions that include swelling of the face, lips, tongue or throat, breathing or swallowing issues, severe rash, itching, dizziness and rapid heartbeat. Anyone who experiences an allergic reaction should seek immediate medical attention. NewsNation's Taylor Delandro contributed to this report.

Are weight loss drugs safe? Learn some of the side effects
Are weight loss drugs safe? Learn some of the side effects

Yahoo

time15-05-2025

  • Yahoo

Are weight loss drugs safe? Learn some of the side effects

(NewsNation) — Weight loss drugs have become an increasingly popular, but controversial, way of quickly shedding extra pounds over the past few years. Part of that controversy deals with the side effects caused by some of the more well-known medications like Ozempic and Mounjaro. According to the Obesity Medicine Association, researchers are continually analyzing the side effects of these drugs. Here are some side effects of the eight FDA-approved weight loss drugs: Ozempic and Wegovy are the brand names of a drug known as semaglutide, a medication that, according to Harvard Health, has been prescribed for about two decades to treat Type 2 diabetes. Ozempic has become controversial over the past few years as overweight and obese patients have sought it out for weight loss, creating a shortage of the drug for those using it to control their diabetes. Wegovy is the brand name for a form of semaglutide that has since been approved for weight loss. Semaglutide, which mimics a natural hormone called GLP-1, helps regulate blood sugar while slowing down the emptying of the stomach and signaling satiety or fullness to the brain. What's the difference between Ozempic, Wegovy, other weight loss drugs? The OMA reports that the most common complaint among patients using semaglutide is gastrointestinal issues like nausea. Other side effects include fatigue, dizziness, headache, bloating, belching and heartburn. An American Medical Association study has also found that GLP-1 agonists are associated with an increased risk of pancreatitis, bowel obstruction, and gastroparesis. While headlines have warned about an increase in suicidal ideation with semaglutide, a January 2024 study in Nature Medicine suggested 'a 49% to 73% lower risk of first-time or recurring suicidal ideations' compared with other obesity medications. Mounjaro and Zepbound are drugs known as tirzepatide. Mounjaro was approved in 2017 to treat Type 2 diabetes, while Zepbound was approved in more recent years to treat obesity. Like semaglutide, tirzepatide is a GLP-1 agonist that increases a person's feeling of fullness and helps them maintain a weight loss diet. Some drugs more effective for weight loss than Ozempic: Study It causes common mild symptoms like nausea, constipation, diarrhea and bloating, but the OMA reports more serious side effects like kidney problems up to and including kidney failure, gallbladder symptoms, pancreatitis and hypoglycemia. Manufacturer Eli Lilly warns, however, that Tirzepatide may cause thyroid tumors or thyroid cancer. Patients should monitor themselves for symptoms like neck swelling, hoarseness, problems swallowing and shortness of breath. Contrave is the brand name for a medication that combines two drugs, bupropion and naltrexone. Bupropion, which is marketed under the brand name Wellbutrin, is an antidepressant that is also known to reduce a person's appetite. Naltrexone, commonly sold under the brand names Revia and Vivitrol, is a medication used to treat drug and alcohol addiction. According to naltrexone works by blocking the euphoric, intoxicated feeling of alcohol and opioids. It also helps reduce the cravings for the substances. FAQ: How do Ozempic, weight-loss drugs work? The OMA reports that patients should not be prescribed Contrave if they suffer from a seizure disorder or if they take opioids for chronic pain. The most common side effects of the drug are nausea, vomiting, constipation, diarrhea, headache, dizziness, dry mouth and insomnia. Saxenda is a medication containing liraglutide, a drug that mimics a person's natural hormones affecting hunger, digestion and feelings of fullness. It was approved by the FDA in 2017 to treat obesity in people 12 and older. The most common side effects of liraglutide are nausea, vomiting, constipation, diarrhea, headache, fatigue, dyspepsia, dizziness and abdominal pain. It can also cause increased heart rate, increased lipase, which is a pancreatic enzyme, and decreased kidney function. Qsymia is a medication that combines the drugs phentermine and topiramate. According to the OMA, phentermine has been around since 1959, making it the oldest and most widely used weight loss medication. The drug, which works in the brain as an appetite suppressant, is a stimulant similar to amphetamines and can be abused. It should not be used by patients who have suffered a stroke or who have heart disease, glaucoma or hyperthyroidism. The side effects of phentermine can be serious, including fast or irregular heart rate, headache, overstimulation, high blood pressure and tremors. It can also interact with several other drugs, including MAO inhibitors, alcohol, adrenergic neuron blockers and some anesthetic agents. How many people use injectable weight loss drugs? When phentermine is combined with topiramate, an anticonvulsant, its effect on hunger is magnified. The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and dry mouth. Topiramate also carries a risk of birth defects, so it should not be taken during pregnancy. Qsymia was approved in 2021 for chronic weight management in adults. It was approved the following year for pediatric patients ages 12 and older who have a body mass index in the 95th percentile or greater. Imcivree, which is the brand name for setmelanotide, is approved by the FDA to treat patients suffering from severe obesity caused by rare genetic disorders. According to the National Institute of Health, setmelanotide is used to treat POMC, PCSK1 and LEPR deficiencies, which all lead to early-onset obesity. According to manufacturer Rhythm Pharmaceuticals, it is also used to treat Bardet-Biedl syndrome in patients aged 2 and older. Setmelanotide works by targeting the impaired MC4R pathway in the brain, which allows it to deliver messages to the brain that the body is satisfied and doesn't need more food. The National Institute of Health reports that it helps restore appetite control, reduces the patient's food intake and helps to control weight gain. About half of Americans approve of using weight-loss drugs: Poll It does not treat the underlying genetic defects that lead to obesity. The most common side effects of Imcivree are reactions at the injection site, hyperpigmentation, nausea, vomiting, headache, diarrhea, stomach pain and depression. More serious side effects include sexual dysfunction, depression, suicidal thoughts or actions and toxicity caused by benzyl alcohol, which is a preservative in Imcivree. Like most medications, it can also cause serious allergic reactions that include swelling of the face, lips, tongue or throat, breathing or swallowing issues, severe rash, itching, dizziness and rapid heartbeat. Anyone who experiences an allergic reaction should seek immediate medical attention. NewsNation's Taylor Delandro contributed to this report. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Ontario's Hospitals to Adapt and Change in the Face of Uncertainty
Ontario's Hospitals to Adapt and Change in the Face of Uncertainty

Yahoo

time15-05-2025

  • Yahoo

Ontario's Hospitals to Adapt and Change in the Face of Uncertainty

Already Facing a Growing Wave of Chronic Disease, U.S. Attack on Ontario Threatens Prosperity, Provincial Revenues TORONTO , May 15, 2025 /CNW/ - "The Ontario Hospital Association (OHA), alongside Ontario's hospitals, welcomes the investments announced for hospitals and the broader health care system in the 2025/2026 Ontario Budget. However, given that the funding requirements of our sector will not be fully met, Ontario's hospitals will be seeking to work closely with the Government of Ontario to adapt during this period of elevated risk and uncertainty. Ontario is balancing a wide range of complex priorities as it grapples with the most serious threat to the province's economy in recent history. As the provincial and federal governments navigate this challenging time, Ontario's hospitals will step up and do their part by working to minimize impact on front-line care. A longer term, multi-year planning and funding approach will be needed so hospitals can plan effectively through the challenging period that lies ahead. Ontario's hospitals are here to care for their communities and will work collaboratively with the Ministry of Health and Ontario Health in prioritizing decision-making. The OHA supports the Government of Ontario plan to strengthen primary care by rostering an additional two million people with a primary care provider by 2029. By 2040, approximately 3.1 million people will be living with a major illness – up from 1.8 million in 2020. A robust system of primary care will give more people access to a health care provider whose job is to focus on disease prevention and the management of chronic conditions. If the strategy is effective, in time, primary care will become the backstop of Ontario's health care system – rather than hospitals - ensuring more people receive care in a more appropriate and cost-effective setting. Over the long term, Ontario's hospitals will continue to adapt and innovate as they always have. Hospitals will look beyond traditional models of care, promote proven scientific, technological, and clinical innovation, and find new ways to ensure its spread and scale. Ontario's hospitals are grateful for the support of the people of Ontario and ask for their ongoing support and understanding in the challenging years that lie ahead." - Anthony Dale, President and CEO, Ontario Hospital Association Ontario Hospital AssociationEstablished in 1924, the OHA serves as the voice of the province's public hospitals, supporting them through advocacy, knowledge translation and member engagement, labour relations, and data and analytics with the goal of helping hospitals build a better health system. The OHA is also attuned to the broader strategic questions facing the future of the province's health care system and we work to ensure Ontario's hospitals have a voice in shaping this longer-term vision. SOURCE Ontario Hospital Association View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store